OCEAN, said Albert, provides important risk-benefit data that doctors can now use in discussions with their patients. For ...

NEW ORLEANS, LA—Among patients with atrial fibrillation (AF) undergoing PCI, 1 month of dual therapy with a direct oral ...

The drug, given as a weekly subcutaneous injection, reduced both triglycerides and liver fat in the phase II trial.

It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

The small-profile device expands to capture clots like large-bore systems while offering good reduction in RV/LV ratio at 48 ...

Follow-up over 10 years may show different patterns, and experts predict DCBs will likely be useful in certain populations.

The NyokAssist device, from China, had few adverse outcomes by 30 days. More devices—and more trials—are on the way.

For the rest of the population without a higher-than-usual risk of hemorrhagic stroke, Gurol said his recommendation is to drink no more than three servings of alcohol per week because consuming more ...

Patrick O’Gara speaks with Sean Pinney about the evaluation and treatment of patients with severe tricuspid regurgitation.

Mamas Mamas and Evald Christiansen discuss the 10-year data comparing DES PCI and CABG for LM disease.